CD37 and non-Hodgkin lymphoma: Moreover, its combination with rituximab demonstrated synergistic tumor suppression in NHL xenograft models, enhancing CD20 expression and potentially improving clinical outcomes with combined CD37- and CD20-targeted therapies [52].